Skip to main content

Table 2 Adverse Events

From: Immunogenicity and safety of a live herpes zoster vaccine in hematopoietic stem cell transplant recipients

  HSCT 2–5 yr
(n = 26)
HSCT > 5 yr
(n = 15)
Chemotherapy (n = 15) Healthy
(n = 30)
Any adverse events, n (%) 5 (19.2) 3 (20.0) 2 (13.3) 0 (0)
Local adverse events, n (%) 4 (15.4) 2 (13.3) 1 (6.6) 0 (0)
 Pain or tenderness 3 (11.5) 2 (13.3) 1 (6.6) 0 (0)
 Redness 3 (11.5) 2 (13.3) 1 (6.6) 0 (0)
 Induration or edema 1 (3.8) 2 (13.3) 1 (6.6) 0 (0)
 Itching 3 (11.5) 2 (13.3) 1 (6.6) 0 (0)
Systemic adverse events, n (%) 3 (11.5) 1 (6.6) 1 (6.6) 0 (0)
 Headache 1 (3.8) 1 (6.6) 0 (0) 0 (0)
 Myalgia or arthralgia 3 (11.5) 1 (6.6) 0 (0) 0 (0)
 Fatigue 3 (11.5) 0 (0) 1 (6.6) 0 (0)
 Fever 0 (0) 0 (0) 0 (0) 0 (0)
 Systemic allergic reaction 0 (0) 0 (0) 0 (0) 0 (0)
 Nausea or vomiting 0 (0) 0 (0) 0 (0) 0 (0)
 Diarrhea 0 (0) 0 (0) 0 (0) 0 (0)
  1. HSCT Hematopoietic stem cell transplantation, N Number
\